Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.

AIDS research and human retroviruses - 10 Feb 2001

Dronda F, Casado J L, Moreno S, Hertogs K, García-Arata I, Antela A, Pérez-Elías M J, Ruiz L, Larder B

Abstract excerpt

Cross-resistance to nelfinavir (NFV) is observed in patients failing protease inhibitor (PI)-containing therapies. We performed a study with 111 patients who started an NFV-based salvage regimen after failing PI-based therapy to evaluate genotypic changes and to identify factors associated with resistance to NFV. Genotypic and phenotypic resistance data at entry (111 and 51 samples) and after NFV failure (74 and...

Topics

Adult
Aged
Anti-HIV Agents
Drug Resistance, Microbial
HIV Infections
HIV Protease
HIV Protease Inhibitors
HIV-1
Humans
Male
Middle Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Nelfinavir

Phenotype

Source

Identifiers

PMID: 11177403
DOI: 10.1089/088922201750063124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.PMID 11177403Read ↗

Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.Semantic proximity Read ↗

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.Semantic proximity Read ↗

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.Semantic proximity Read ↗

HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens.Semantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.Semantic proximity Read ↗

Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations.Semantic proximity Read ↗

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.Semantic proximity Read ↗

Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.Semantic proximity Read ↗

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.